Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)
Por um escritor misterioso
Descrição
Inhibition of MGAT2 modulates fat‐induced gut peptide release and
Full article: Patent landscape for discovery of promising
BMS-963272Cas# 1441057-15-3
Novel antisense inhibition of diacylglycerol O-acyltransferase 2
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the
Metabolic Targets in Nonalcoholic Steatohepatitis: Treating the
Targeting diacylglycerol acyltransferase 2 for the treatment of
Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the
de
por adulto (o preço varia de acordo com o tamanho do grupo)
